
| # | Concept | H-Index | Publications | Citations |
|---|---|---|---|---|
1 | Engineering | 282 | 31.2K | 1.8M |
2 | Health Sciences | 120 | 4.5K | 238.9K |
3 | Business | 110 | 1.2K | 80.6K |
4 | Education | 98 | 1.6K | 88.6K |
5 | Arts | 71 | 545 | 31.5K |
Universidad Autónoma de Madrid
×
120.5K
Publications
9.1M
Citations
| Year | Citations | |
|---|---|---|
2002 | 11.7K | |
2018 | 10.7K | |
2012 | 10.4K | |
2007 | 7.6K | |
2018 | 7K | |
2015 | 5.7K | |
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Rafael Rosell, Enric Carcereny, Radj Gervais, OncologyStandard ChemotherapyRandomised Phase 3PathologyBronchial Neoplasm | 2012 | 5.5K |
2011 | 4.4K | |
2019 | 4.2K | |
2006 | 4.1K |
Page 1
Page 1